首页> 美国卫生研究院文献>Acta Pharmaceutica Sinica. B >Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods
【2h】

Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods

机译:通过计算方法分析SARS-CoV-2的治疗靶点并发现潜在药物

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

SARS-CoV-2 has caused tens of thousands of infections and more than one thousand deaths. There are currently no registered therapies for treating coronavirus infections. Because of time consuming process of new drug development, drug repositioning may be the only solution to the epidemic of sudden infectious diseases. We systematically analyzed all the proteins encoded by SARS-CoV-2 genes, compared them with proteins from other coronaviruses, predicted their structures, and built 19 structures that could be done by homology modeling. By performing target-based virtual ligand screening, a total of 21 targets (including two human targets) were screened against compound libraries including ZINC drug database and our own database of natural products. Structure and screening results of important targets such as 3-chymotrypsin-like protease (3CLpro), Spike, RNA-dependent RNA polymerase (RdRp), and papain like protease (PLpro) were discussed in detail. In addition, a database of 78 commonly used anti-viral drugs including those currently on the market and undergoing clinical trials for SARS-CoV-2 was constructed. Possible targets of these compounds and potential drugs acting on a certain target were predicted. This study will provide new lead compounds and targets for further and studies of SARS-CoV-2, new insights for those drugs currently ongoing clinical studies, and also possible new strategies for drug repositioning to treat SARS-CoV-2 infections.
机译:SARS-CoV-2造成了成千上万的感染,超过一千的死亡。目前尚无用于治疗冠状病毒感染的注册疗法。由于新药开发过程耗时,重新定位药物可能是解决突发传染病流行的唯一方法。我们系统地分析了SARS-CoV-2基因编码的所有蛋白质,将它们与其他冠状病毒的蛋白质进行比较,预测了它们的结构,并构建了19个可以通过同源性建模完成的结构。通过执行基于靶标的虚拟配体筛选,针对包括ZINC药物数据库和我们自己的天然产物数据库在内的化合物库,共筛选了21个靶标(包括两个人类靶标)。详细讨论了诸如3-胰凝乳蛋白酶样蛋白酶(3CLpro),Spike,RNA依赖性RNA聚合酶(RdRp)和木瓜蛋白酶样蛋白酶(PLpro)等重要靶标的结构和筛选结果。此外,还建立了78种常用抗病毒药物的数据库,包括目前在市场上进行抗SARS-CoV-2临床试验的抗病毒药物。预测了这些化合物的可能目标以及作用于某个目标的潜在药物。这项研究将为SARS-CoV-2的进一步研究提供新的先导化合物和靶标,为当前正在进行的临床研究提供新的见识,并为治疗SARS-CoV-2感染的药物重新定位提供可能的新策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号